This groundbreaking vaccine is built upon vaccine antigen technology jointly developed by researchers from the University of Cambridge and the biotech company, Diosynvax Ltd.
The key to this vaccine’s potential success lies in its focus on the spike proteins found on the surface of all SARS-CoV-2 virus variants. These spike proteins are crucial for the virus’s ability to enter and infect host cells. While current vaccines target these spike proteins, they can only offer protection against previously identified virus variants.
The challenge arises because spike proteins constantly mutate, leading to the emergence of new variants. Traditional vaccines that target specific spike proteins may become obsolete as the virus evolves. However, this innovative vaccine aims to provide broader protection by targeting a fundamental aspect shared by all variants, potentially offering a solution to the ever-changing landscape of COVID-19 variants.
